Daiichi Sankyo, Inc. is the U.S. subsidiary of Daiichi Sankyo, Co., Ltd.
Daiichi Sankyo, Inc. medicines approved in the U.S. include therapies for hypertension, pain management, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma.
Subsidiary
Companies owned by Daiichi Sankyo that operate as distinct brands.